Could hormone therapy after menopause help protect the aging brain? A new study published in Neurology, the medical journal of the American Academy of Neurology, adds fresh evidence to one of the most contested questions in women’s health. Researchers report that postmenopausal women who used estrogen-only hormone therapy had roughly 35% lower odds of showing brain changes associated with Alzheimer’s disease compared with women who never used it.
The findings, released in August 2026, are drawing attention because dementia disproportionately affects women, who make up nearly two-thirds of Americans living with Alzheimer’s disease, according to the Alzheimer’s Association. But scientists — including the study’s own authors — caution that the results are observational and not a green light for using hormone therapy as a dementia prevention tool.
What the Stanford Team Found
Led by Jennifer Bruno, PhD, of Stanford University School of Medicine, the research team analyzed two large longitudinal datasets used widely in Alzheimer’s research: the National Alzheimer’s Coordinating Center (NACC) database and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Combined, the analysis included nearly 5,000 postmenopausal women with an average age of 71 to 72.
Within the NACC dataset, 258 women who had used estrogen-only therapy were compared with 2,701 non-users. In ADNI, 110 users were compared with 1,948 non-users. Researchers looked at brain autopsy data and neuroimaging biomarkers linked to Alzheimer’s, including amyloid plaques, tau tangles, and overall amyloid load.
Women who had used estrogen-only therapy showed:
- About 35% lower odds of Alzheimer’s-related brain pathology
- Lower dementia diagnosis rates over follow-up
- Better performance on memory tests, particularly immediate memory and learning
- Improved verbal memory among women without dementia
Not All Estrogen Types Showed the Same Effect
One of the more nuanced findings involved the type of hormone used. Women who took conjugated estrogens — a form derived from equine sources and long used in menopausal therapy — showed the protective association with lower Alzheimer’s neuropathology. Women taking estradiol, a bioidentical form, had brain pathology levels similar to non-users. The reasons for the difference are unclear and will need further investigation.
The APOE Gene Matters
Genetics also played a role. Women who did not carry the APOE e4 gene variant — the strongest known genetic risk factor for late-onset Alzheimer’s — appeared to derive the neuropathological benefit. Carriers of APOE e4 did not show the same association, suggesting that genetic background may modify how estrogen affects the brain.
Why Estrogen and Alzheimer’s Are Being Studied Together
Estrogen receptors are found throughout the brain, including in regions critical for memory and executive function such as the hippocampus and prefrontal cortex. The hormone influences synaptic plasticity, glucose metabolism, and inflammation — all pathways implicated in Alzheimer’s pathology, according to a review in Frontiers in Aging Neuroscience.
When ovarian estrogen production drops sharply during menopause, some researchers have hypothesized that the brain loses a form of biochemical protection. That hypothesis has been debated for decades. Early observational studies in the 1990s suggested hormone therapy might guard against dementia, but the landmark Women’s Health Initiative Memory Study (WHIMS), published in JAMA in 2003, found that combined estrogen-plus-progestin therapy in women 65 and older actually increased dementia risk.
Subsequent analyses have suggested a “critical window” hypothesis: that timing matters, and hormone therapy started closer to menopause may behave differently than therapy started years later. The new Stanford analysis contributes to that ongoing conversation but does not resolve it.
Important Caveats Before Drawing Conclusions
Independent experts urged restraint in interpreting the findings. “The findings do not support prescribing menopausal hormone therapy specifically to prevent Alzheimer’s disease or dementia,” said Dr. Dung Trinh in comments accompanying the study, noting that only randomized controlled trials can establish cause and effect.
Several limitations stand out:
- Observational design. The study can only show an association, not prove that estrogen therapy caused the reduced brain pathology.
- Self-reported data. Participants recalled their hormone therapy use, timing, and dose, which introduces potential recall bias.
- Narrow eligibility. Estrogen-only therapy is typically prescribed to women who have undergone hysterectomy. Women with an intact uterus require progestin alongside estrogen to reduce endometrial cancer risk.
- Limited diversity. Both datasets skewed predominantly white, limiting how well findings apply to other populations.
- Missing timing data. Researchers could not always determine when hormone therapy began or how long women stayed on it.
What the Current Guidelines Say
The North American Menopause Society (now The Menopause Society) currently recommends hormone therapy for treating bothersome menopausal symptoms such as hot flashes, night sweats, and genitourinary syndrome of menopause — not for chronic disease prevention. The 2022 position statement emphasizes that benefits generally outweigh risks for symptomatic women under 60 or within 10 years of menopause onset who do not have contraindications.
The U.S. Preventive Services Task Force similarly recommends against using hormone therapy for the primary prevention of chronic conditions in postmenopausal women, citing insufficient evidence of benefit and known risks such as stroke and blood clots.
What This Means for Women Considering Hormone Therapy
The new research is unlikely to change prescribing guidelines on its own. But it adds to a growing body of work suggesting that questions about hormones and brain health deserve more rigorous investigation, particularly in women who begin therapy near menopause and who do not carry the APOE e4 variant.
For women currently weighing hormone therapy for menopausal symptoms, the practical takeaway is that decisions should continue to be individualized. Factors that typically inform the conversation include:
- Severity of vasomotor symptoms and impact on quality of life
- Age and time since menopause onset
- Personal and family history of breast cancer, cardiovascular disease, and blood clots
- Whether the uterus is intact (which determines the need for progestin)
- Preferred delivery method (oral, transdermal patch, gel, or vaginal)
Other Evidence-Based Strategies for Brain Health
Regardless of hormone therapy decisions, research strongly supports several habits that appear to lower dementia risk across populations. A 2024 Lancet Commission report identified 14 modifiable risk factors accounting for an estimated 45% of dementia cases worldwide, including physical inactivity, hearing loss, high blood pressure, obesity, smoking, and social isolation.
Practical, well-supported strategies include:
- Regular aerobic and resistance exercise
- A Mediterranean-style eating pattern rich in vegetables, fish, olive oil, and legumes
- Prioritizing sleep quality and treating sleep apnea if present
- Managing blood pressure, cholesterol, and blood sugar
- Staying cognitively and socially engaged
- Correcting hearing loss with hearing aids when appropriate
The Bottom Line
Studies indicate that estrogen may play a role in brain aging, and the Stanford analysis strengthens the case for further research into how hormone therapy timing, type, and genetic background interact. But research suggests the current evidence base is not sufficient to recommend hormone therapy solely for Alzheimer’s prevention. Women considering hormone therapy — for menopausal symptoms or any other reason — should have a personalized conversation with a qualified clinician who can weigh their individual risks and benefits.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.